Top

Published in:

Open Access 01-12-2014 | Clinical Guides in Oncology

Clinical guideline SEOM: cancer of unknown primary site

Authors: R. Collado Martín, A. García Palomo, L. de la Cruz Merino, P. Borrega García, F. J. Barón Duarte

Published in: Clinical and Translational Oncology | Issue 12/2014

Abstract

Cancer of unknown primary site is a histologically confirmed cancer which is manifested in advanced stage, with no identifiable primary site after the use of standard diagnostic procedures. Patients are initially placed into one of categories based upon the examination of the initial biopsy: adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and poorly differentiated carcinoma. Appropriate patient management requires an understanding of several clinicopathologic features that help to identify several subsets of patients with more responsive tumors.

Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109(2):292.PubMedCrossRef

Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott; 2008. p. 2363–87.

Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol. 2010;21(Suppl 7):vii303–7.

Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. French study group on carcinomas of unknown primary. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20(24):4679–83.PubMedCrossRef

Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731–44.PubMedCentralPubMedCrossRef

Catena L, Bichisao E, Milione M, Valente M, Platania M, Pusceddu S, et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms? Tumori. 2011;97(5):564.PubMed

Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012;84(2):213–23.PubMedCrossRef

Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Loannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta análisis. Cancer Treat Rev. 2009;35:570–3.PubMedCrossRef

NCCN clinical practice guidelines in oncology. Occult primary (cancer of unkonwn primary). Vers 3.2014. [Internet]. Washington: National comprehensive cancer network. Available in: http://www.nccn.org/professionals/physiciangls/fguidelines.asp accessed May 13 2014.

10.

Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized phase III Sarah Cannon Research Consortium Trial. Cancer J. 2010;16:70–5.PubMedCrossRef

11.

Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—Trial for the French study group on carcinomas of unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479–82.PubMedCrossRef

12.

Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with colon-cancer profile: changing paradigm and emerging definitions. Lancet Oncol. 2008;9:596–9.PubMedCrossRef

13.

Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol. 2009;36:6.PubMedCrossRef

14.

Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G ESMO guidelines working group. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi64–8.

15.

NCCN clinical practice guidelines in oncology. Occult primary (Cancer of unkonwn primary). Version .2014. [Internet]. Washington: National comprehensive cancer network. Available in: http://www.nccn.org/professionals/physiciangls/fguidelines.asp. Accessed May 13 2014.

16.

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the issue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospectivetrial of the Sarah Cannon research Institute. J Clin Oncol. 2013;31:217.PubMedCrossRef

17.

Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol. 2009;36:6.PubMedCrossRef

Title: Clinical guideline SEOM: cancer of unknown primary site
Authors: R. Collado Martín
A. García Palomo
L. de la Cruz Merino
P. Borrega García
F. J. Barón Duarte
Publication date: 01-12-2014
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 12/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1244-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

SEOM clinical guidelines for the treatment of renal cell carcinoma

SEOM guidelines 2014: improving quality to increase its usefulness

Thyroid cancer: SEOM clinical guidelines

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

SEOM Clinical guidelines for the treatment of metastatic prostate cancer

SEOM guidelines on hydroelectrolytic disorders

Keynote webinar | Spotlight on antibody–drug conjugates in cancer